CoChat

Adult-Onset Hypogonadism

Open access
Khera, Mohit, Broderick, Gregory A., Carson, Culley C., Dobs, Adrian S., Faraday, Martha M., Goldstein, Irwin, Hakim, Lawrence S., Hellstrom, Wayne J.G., Kacker, Ravi, Köhler, Tobias S., Mills, Jesse N., Miner, Martin, Sadeghi-Nejad, Hossein, Seftel, Allen D., Sharlip, Ira D., Winters, Stephen J., Burnett, Arthur L. · 2016 · Mayo Clinic Proceedings
Cited by 96

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

In August 2015, an expert colloquium commissioned by the Sexual Medicine Society of North America (SMSNA) convened in Washington, DC, to discuss the common clinical scenario of men who present with low testosterone (T) and associated signs and symptoms accompanied by low or normal gonadotropin levels. This syndrome is not classical primary (testicular failure) or secondary (pituitary or hypothalamic failure) hypogonadism because it may have elements of both presentations. The panel designated this syndrome adult-onset hypogonadism (AOH) because it occurs commonly in middle-age and older men. The SMSNA is a not-for-profit society established in 1994 to promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of human sexual function and dysfunction. The panel consisted of 17 experts in men's health, sexual medicine, urology, endocrinology, and methodology. Participants declared potential conflicts of interest and were SMSNA members and nonmembers. The panel deliberated regarding a diagnostic process to document signs and symptoms of AOH, the rationale for T therapy, and a monitoring protocol for T-treated patients. The evaluation and management of hypogonadal syndromes have been addressed in recent publications (ie, the Endocrine Society, the American Urological Association, and the International Society for Sexual Medicine). The primary purpose of this document was to support health care professionals in the development of a deeper understanding of AOH, particularly in how it differs from classical primary and secondary hypogonadism, and to provide a conceptual framework to guide its diagnosis, treatment, and follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2016.04.022

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 88

  1. Dean, 2015, The International Society for Sexual Medicine's process of care for the assessment and management of testosterone deficiency in adult men, J Sex Med, 12, 1660
  2. Guay, 2010, Hypogonadism in men with erectile dysfunction may be related to a host of chronic illnesses, Int J Impot Res, 22, 9, 10.1038/ijir.2009.46 · DOI
  3. Maseroli, 2015, Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study, J Sex Med, 12, 956
  4. Corona, 2014, Characteristics of compensated hypogonadism in patients with sexual dysfunction, J Sex Med, 11, 1823
  5. Nieschlag, 1982, Reproductive functions in young fathers and grandfathers, J Clin Endocrinol Metab, 55, 676, 10.1210/jcem-55-4-676 · DOI · Paper page
  6. Yeap, 2009, Healthier lifestyle predicts higher circulating testosterone in older men: the Health In Men Study, Clin Endocrinol (Oxf), 70, 455, 10.1111/j.1365-2265.2008.03372.x · DOI · Paper page
  7. Rubens, 1974, Further studies on Leydig cell function in old age, J Clin Endocrinol Metab, 39, 40, 10.1210/jcem-39-1-40 · DOI · Paper page
  8. Araujo, 2011, Endocrinology of the aging male, Best Pract Res Clin Endocrinol Metab, 25, 303, 10.1016/j.beem.2010.11.004 · DOI · Paper page
  9. Takahashi, 2005, Graded inhibition of pulsatile luteinizing hormone secretion by a selective gonadotropin-releasing hormone (GnRH)-receptor antagonist in healthy men: evidence that age attenuates hypothalamic GnRH outflow, J Clin Endocrinol Metab, 90, 2768, 10.1210/jc.2004-2521 · DOI
  10. Winters, 1997, Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group, Clin Endocrinol (Oxf), 47, 317, 10.1046/j.1365-2265.1997.2551065.x · DOI · Paper page
  11. Zumoff, 1982, Age variation of the 24 hour mean plasma concentration of androgens, estrogens, and gonadotropins in normal adult men, J Clin Endocrinol Metab, 54, 534, 10.1210/jcem-54-3-534 · DOI · Paper page
  12. MacDonald, 2010, The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis, Hum Reprod Update, 16, 293, 10.1093/humupd/dmp047 · DOI · Paper page
  13. Faris, 2010, Metabolic sequelae associated with androgen deprivation therapy for prostate cancer, Curr Opin Endocrinol Diabetes Obes, 17, 240, 10.1097/MED.0b013e3283391fd1 · DOI · Paper page
  14. Shores, 2006, Low serum testosterone and mortality in male veterans, Arch Intern Med, 166, 1660, 10.1001/archinte.166.15.1660 · DOI · Paper page
  15. Corona, 2006, Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction, Eur Urol, 50, 595, 10.1016/j.eururo.2006.02.053 · DOI · Paper page
  16. Ashby, 2014, Hypogonadism in human immunodeficiency virus-positive men, Korean J Urol, 55, 9, 10.4111/kju.2014.55.1.9 · DOI
  17. Crum-Cianflone, 2007, Erectile dysfunction and hypogonadism among men with HIV, AIDS Patient Care STDS, 21, 9, 10.1089/apc.2006.0071 · DOI · Paper page
  18. De Ryck, 2013, Erectile dysfunction, testosterone deficiency, and risk of coronary heart disease in a cohort of men living with HIV in Belgium, J Sex Med, 10, 1816
  19. Moreno-Pérez, 2009, Hypogonadism, erectile dysfunction and endothelial dysfunction among HIV-infected men, Med Clin (Barc), 132, 311, 10.1016/j.medcli.2008.07.018 · DOI
  20. Richardson, 2007, Letrozole versus testosterone: a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels, J Sex Med, 4, 502
  21. Rochira, 2011, Premature decline of serum total testosterone in HIV-infected men in the HAART-era, PLoS One, 6, e28512, 10.1371/journal.pone.0028512 · DOI · Paper page
  22. Sadeghi-Nejad, 2010, Sexually transmitted diseases and sexual function, J Sex Med, 7, 389
  23. Tripathy, 2015, Endocrine alterations in HIV-infected patients, Indian J Endocrinol Metab, 19, 143, 10.4103/2230-8210.146870 · DOI
  24. Zona, 2012, Erectile dysfunction is more common in young to middle-aged HIV-infected men than in HIV-uninfected men, J Sex Med, 9, 1923
  25. Thompson, 1994, Prevention of male infertility, Urol Clin North Am, 21, 365, 10.1016/S0094-0143(21)00613-3 · doi:10.1016/s0094-0143(21)00613-3
  26. Rahnema, 2014, Anabolic steroid-induced hypogonadism: diagnosis and treatment, Fertil Steril, 101, 1271, 10.1016/j.fertnstert.2014.02.002 · DOI · Paper page
  27. Birthi, 2015, Hypogonadism associated with long-term opioid therapy: a systematic review, J Opioid Manag, 11, 255, 10.5055/jom.2015.0274 · DOI
  28. Schooling, 2013, The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials, BMC Med, 11, 57, 10.1186/1741-7015-11-57 · DOI · Paper page
  29. Howell, 2005, Spermatogenesis after cancer treatment: damage and recovery, J Natl Cancer Inst Monogr, 34, 12, 10.1093/jncimonographs/lgi003 · DOI · Paper page
  30. Attal, 2010, Endocrine aspects of obstructive sleep apnea, J Clin Endocrinol Metab, 95, 483, 10.1210/jc.2009-1912 · DOI · Paper page
  31. Luboshitzky, 2002, Decreased pituitary-gonadal secretion in men with obstructive sleep apnea, J Clin Endocrinol Metab, 87, 3394, 10.1210/jcem.87.7.8663 · doi:10.1210/jcem.87.7.8663 · Paper page
  32. Baum, 1982, The use of psychological and neuroendocrinological measurements in the study of stress, Health Psychol, 1, 217, 10.1037/0278-6133.1.3.217 · DOI
  33. Nilsson, 1995, Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males, J Intern Med, 237, 479, 10.1111/j.1365-2796.1995.tb00873.x · DOI · Paper page
  34. Singer, 1992, Subnormal serum testosterone levels in male internal medicine residents, Steroids, 57, 86, 10.1016/0039-128X(92)90035-8 · DOI
  35. Kalinchenko, 2010, Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study, Clin Endocrinol (Oxf), 73, 602, 10.1111/j.1365-2265.2010.03845.x · DOI · Paper page
  36. Aversa, 2010, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study, J Sex Med, 7, 3495
  37. Gianatti, 2014, Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial, Diabetes Care, 37, 2098, 10.2337/dc13-2845 · DOI · Paper page
  38. Gopal, 2010, Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus, Endocr Pract, 16, 570, 10.4158/EP09355.OR · DOI
  39. Hammoud, 2009, Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men, J Clin Endocrinol Metab, 94, 1329, 10.1210/jc.2008-1598 · DOI · Paper page
  40. Anderson, 1974, Sex-hormone-binding globulin, Clin Endocrinol (Oxf), 3, 69, 10.1111/j.1365-2265.1974.tb03298.x · DOI · Paper page
  41. Le M, Flores D, May D et al. Current practices of measuring and reference range reporting of free and total testosterone in the United States [published online ahead of print December 18, 2015]. J Urol. 2016;195:1556-1561. · DOI
  42. Shea, 2014, Free testosterone: clinical utility and important analytical aspects of measurement, Adv Clin Chem, 63, 59, 10.1016/B978-0-12-800094-6.00002-9 · DOI
  43. Dandona, 2010, A practical guide to male hypogonadism in the primary care setting, Int J Clin Pract, 64, 682, 10.1111/j.1742-1241.2010.02355.x · DOI · Paper page
  44. Buvat, 2013, Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment, J Sex Med, 10, 245
  45. Rosen, 2011, The NERI Hypogonadism Screener: psychometric validation in male patients and controls, Clin Endocrinol (Oxf), 74, 248, 10.1111/j.1365-2265.2010.03925.x · DOI · Paper page
  46. Hak, 2002, Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study, J Clin Endocrinol Metab, 87, 3632, 10.1210/jcem.87.8.8762 · doi:10.1210/jcem.87.8.8762 · Paper page
  47. Haddad, 2007, Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials, Mayo Clin Proc, 82, 29, 10.1016/S0025-6196(11)60964-6 · DOI · Paper page
  48. Xu, 2013, Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials, BMC Med, 11, 108, 10.1186/1741-7015-11-108 · DOI · Paper page
  49. Layton, 2015, Comparative safety of testosterone dosage forms, JAMA Intern Med, 175, 1187, 10.1001/jamainternmed.2015.1573 · DOI · Paper page
  50. Isom-Batz, 2005, Testosterone as a predictor of pathological stage in clinically localized prostate cancer, J Urol, 173, 1935
  51. Schatzl, 2003, Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer, J Urol, 169, 1312
  52. Hsing, 2001, Hormones and prostate cancer: what's next?, Epidemiol Rev, 23, 42, 10.1093/oxfordjournals.epirev.a000795 · DOI · Paper page
  53. Roddam, 2008, Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies, J Natl Cancer Inst, 100, 170, 10.1093/jnci/djm323 · DOI · Paper page
  54. Yamamoto, 2007, Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy, Eur Urol, 52, 696, 10.1016/j.eururo.2007.03.052 · DOI
  55. Khera, 2014, A new era of testosterone and prostate cancer: from physiology to clinical implications, Eur Urol, 65, 115, 10.1016/j.eururo.2013.08.015 · DOI · Paper page
  56. Morgentaler, 2011, Testosterone therapy in men with untreated prostate cancer, J Urol, 185, 1256
  57. Song, 2014, Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro, Asian J Androl, 16, 864, 10.4103/1008-682X.129132 · doi:10.4103/1008-682x.129132
  58. Sonnenschein, 1989, Negative controls of cell proliferation: human prostate cancer cells and androgens, Cancer Res, 49, 3474
  59. Chuu, 2005, Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice, Cancer Res, 65, 2082, 10.1158/0008-5472.CAN-04-3992 · DOI
  60. Schweizer, 2015, Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study, Sci Transl Med, 7, 269ra2, 10.1126/scitranslmed.3010563 · DOI · Paper page
  61. Gooren, 2007, Diagnosing and treating testosterone deficiency in different parts of the world: results from global market research, Aging Male, 10, 173, 10.1080/13685530701600885 · DOI
  62. Moore, 2015, Testosterone replacement therapy on the natural history of prostate disease, Curr Urol Rep, 16, 51, 10.1007/s11934-015-0526-6 · DOI
  63. van der Sluis, 2012, Intraprostatic testosterone and dihydrotestosterone, part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer, BJU Int, 109, 176, 10.1111/j.1464-410X.2011.10651.x · DOI
  64. Page, 2011, Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial, J Clin Endocrinol Metab, 96, 430, 10.1210/jc.2010-1865 · DOI · Paper page
  65. Pechersky, 2002, Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume, Int J Androl, 25, 119, 10.1046/j.1365-2605.2002.00335.x · DOI · Paper page
  66. Vignozzi, 2012, Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells, J Endocrinol, 214, 31, 10.1530/JOE-12-0142 · DOI · Paper page
  67. Amano, 2010, Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients, Aging Male, 13, 242, 10.3109/13685538.2010.487552 · DOI
  68. Francomano, 2014, Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome, Urology, 83, 167, 10.1016/j.urology.2013.08.019 · DOI
  69. Haider, 2009, Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men, Andrologia, 41, 7, 10.1111/j.1439-0272.2008.00880.x · DOI
  70. Kalinchenko, 2008, Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study, Aging Male, 11, 57, 10.1080/13685530801953994 · DOI
  71. Karazindiyanoğlu, 2008, The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism, Aging Male, 11, 146, 10.1080/13685530802290438 · DOI
  72. Pearl, 2013, Testosterone supplementation does not worsen lower urinary tract symptoms, J Urol, 190, 1828
  73. Shigehara, 2011, Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study, Aging Male, 14, 53, 10.3109/13685538.2010.518178 · DOI · Paper page
  74. 1990, Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility, Lancet, 336, 955, 10.1016/0140-6736(90)92416-F · DOI · Paper page
  75. Page, 2006, Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist, J Clin Endocrinol Metab, 91, 4374, 10.1210/jc.2006-1411 · DOI · Paper page
  76. Gu, 2009, Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men, J Clin Endocrinol Metab, 94, 1910, 10.1210/jc.2008-1846 · DOI · Paper page
  77. Ko, 2012, Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association, J Urol, 187, 973
  78. Kennedy, 1962, Stimulation of erythropoiesis by androgenic hormones, Ann Intern Med, 57, 917, 10.7326/0003-4819-57-6-917 · DOI
  79. Delev, 2013, Effect of testosterone propionate on erythropoiesis after experimental orchiectomy, Folia Med (Plovdiv), 55, 51, 10.2478/folmed-2013-0017 · DOI
  80. Swerdloff, 2003, Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel, Aging Male, 6, 207, 10.1080/tam.6.3.207.211 · doi:10.1080/tam.6.3.207.211 · Paper page
  81. Bachman, 2014, Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point, J Gerontol A Biol Sci Med Sci, 69, 725, 10.1093/gerona/glt154 · DOI · Paper page
  82. Siddique, 2004, Reversal of polycythaemia induced by intramuscular androgen replacement using transdermal testosterone therapy, Clin Endocrinol (Oxf), 60, 143, 10.1111/j.1365-2265.2004.01933.x · DOI
  83. Jick, 2013, The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UK-based general practice research database, Br J Clin Pharmacol, 75, 260, 10.1111/j.1365-2125.2012.04326.x · DOI
  84. Schreijer, 2010, High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander?, Haematologica, 95, 182, 10.3324/haematol.2009.017285 · DOI
  85. Braekkan, 2010, Hematocrit and risk of venous thromboembolism in a general population. The Tromso study, Haematologica, 95, 270, 10.3324/haematol.2009.008417 · DOI · Paper page
  86. Vayá, 2013, Hemorheological parameters as independent predictors of venous thromboembolism, Clin Hemorheol Microcirc, 53, 131, 10.3233/CH-2012-1581 · DOI
  87. De Stefano, 2008, Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments, Haematologica, 93, 372, 10.3324/haematol.12053 · DOI · Paper page
  88. Glueck, 2014, Testosterone, thrombophilia, thrombosis, Blood Coagul Fibrinolysis, 25, 683, 10.1097/MBC.0000000000000126 · DOI

Cited by

See all 96

Metadata

Authors
Khera, M., Broderick, G. A., Carson, C. C., Dobs, A. S., Faraday, M. M., Goldstein, I., Hakim, L. S., Hellstrom, W. J. G., Kacker, R., Köhler, T. S., Mills, J. N., Miner, M., Sadeghi-Nejad, H., Seftel, A. D., Sharlip, I. D., Winters, S. J., & Burnett, A. L.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2016-07
Volume
91
Issue
7
Pages
908-926
ISSN
0025-6196 (ISSN-L)
OpenAlex
W2468038015
Cited by
96
References
57
FWCI
9.53
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adult-Onset Hypogonadism. https://app.cochat.ai/papers/10.1016/j.mayocp.2016.04.022
The paper
Khera, M., Broderick, G. A., Carson, C. C., Dobs, A. S., Faraday, M. M., Goldstein, I., Hakim, L. S., Hellstrom, W. J. G., Kacker, R., Köhler, T. S., Mills, J. N., Miner, M., Sadeghi-Nejad, H., Seftel, A. D., Sharlip, I. D., Winters, S. J., & Burnett, A. L. (2016). Adult-Onset Hypogonadism. Mayo Clinic Proceedings. https://doi.org/10.1016/j.mayocp.2016.04.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.